{"id":27917,"date":"2024-04-19T14:04:31","date_gmt":"2024-04-19T12:04:31","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=27917"},"modified":"2024-04-19T14:04:31","modified_gmt":"2024-04-19T12:04:31","slug":"i-kompensuojamuju-vaistu-rezervini-sarasa-itraukti-nauji-vaistai-skirti-gydyti-cistine-fibroze","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2024\/04\/19\/i-kompensuojamuju-vaistu-rezervini-sarasa-itraukti-nauji-vaistai-skirti-gydyti-cistine-fibroze\/","title":{"rendered":"\u012e kompensuojam\u0173j\u0173 vaist\u0173 rezervin\u012f s\u0105ra\u0161\u0105 \u012ftraukti nauji vaistai, skirti gydyti cistin\u0119 fibroz\u0119"},"content":{"rendered":"
\n

Vaistini\u0173 preparat\u0173 ir medicinos pagalbos priemoni\u0173 kompensavimo komisija ketvirtadien\u012f nusprend\u0117 \u012ftraukti naujus cistinei fibrozei gydyti skirtus preparatus \u012f Rezervin\u012f vaist\u0173 s\u0105ra\u0161\u0105. Kompensuojamieji vaistai pasieks pacientus, kai Privalomojo sveikatos draudimo fondo (PSDF) biud\u017eete bus numatytos l\u0117\u0161os \u0161iems vaistams kompensuoti.<\/strong><\/p>\n

Ivakaftoro, tezakaftoro ir eleksakaftoro su ivakaftoru (Kaftrio su Kalydeco) registruota indikacija numato, kad jis skiriamas 6 met\u0173 ir vyresniems pacientams, sergantiems cistine fibroze, kuriems yra nustatyta bent viena CFTR geno F508del mutacija. Ta\u010diau vaistai bus kompensuojami ne visiems pacientams, kaip numato registruota indikacija, bet tik tiems, kuriems j\u0173 reikia labiausiai ir kurie atitinka nustatytas papildomas skyrimo s\u0105lygas. Jos buvo i\u0161grynintos kartu su sveikatos prie\u017ei\u016bros specialistais, atsi\u017evelgiant \u012f valstyb\u0117s finansines galimybes.<\/p>\n

Valstybin\u0117s ligoni\u0173 kasos skai\u010diavimais, prognozuojamos PSDF biud\u017eeto i\u0161laidos vaistiniams preparatams Kaftrio ir Kalydeco sudaryt\u0173 apie 6,13\u20138,41 mln. Eur pirmaisiais\u2013penktaisiais \u0161i\u0173 vaistini\u0173 preparat\u0173 kompensavimo metais, jei jais b\u016bt\u0173 gydomi 35\u201348 pacientai.<\/p>\n

Cistin\u0117 fibroz\u0117 yra reta genetin\u0117 liga, kai sutrikus liauk\u0173 veiklai pa\u017eeid\u017eiamos kit\u0173 organ\u0173, toki\u0173 kaip plau\u010diai arba kasa, funkcijos. Nuo 2022 met\u0173 sausio visi naujagimiai Lietuvoje yra tiriami d\u0117l \u0161ios retos ligos.<\/p>\n

Cistin\u0117s fibroz\u0117s gydymui \u0161iuo metu yra kompensuojami sistemi\u0161kai veikiantys antibakteriniai vaistai, kv\u0117pavimo sistem\u0105 veikiantys vaistai, ferment\u0173 preparatai \u2013 i\u0161 viso 11 veikli\u0173j\u0173 med\u017eiag\u0173. 2023 m. kompensuojamaisiais vaistais i\u0161 Kompensuojam\u0173j\u0173 vaist\u0173 A s\u0105ra\u0161o nuo cistin\u0117s fibroz\u0117s buvo gydytas 71 pacientas. Privalomojo sveikatos draudimo fondo i\u0161laidos \u0161iems vaistams kompensuoti sudar\u0117 239,77 t\u016bkst. eur\u0173.<\/p>\n

SAM Komunikacijos skyrius<\/em><\/a><\/p>\n<\/div>\n

\n

Atnaujinimo data: 2024-04-19<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Vaistini\u0173 preparat\u0173 ir medicinos pagalbos priemoni\u0173 kompensavimo komisija ketvirtadien\u012f nusprend\u0117 \u012ftraukti naujus cistinei fibrozei gydyti skirtus preparatus \u012f Rezervin\u012f vaist\u0173 s\u0105ra\u0161\u0105. Kompensuojamieji vaistai pasieks pacientus, kai Privalomojo sveikatos draudimo fondo (PSDF) biud\u017eete bus numatytos l\u0117\u0161os \u0161iems vaistams kompensuoti. Ivakaftoro, tezakaftoro ir eleksakaftoro su ivakaftoru (Kaftrio su Kalydeco) registruota indikacija numato, kad jis skiriamas 6 met\u0173…<\/p>","protected":false},"author":3,"featured_media":27918,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[6],"tags":[],"class_list":["post-27917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-naujienos","category-6","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-7gh","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2024\/04\/23Ntd32exJgt.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/27917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=27917"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/27917\/revisions"}],"predecessor-version":[{"id":27919,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/27917\/revisions\/27919"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/27918"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=27917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=27917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=27917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}